| 翻訳と辞書 |
HybriCell
HybriCell is a therapeutic vaccine developed by Brazilian immunologist Jose Alexandre Barbuto. The treatment, which inhibits the division of cancer cells, is aimed at patients in later stages of kidney cancer or melanoma. The vaccine works by extracting certain leukocytes from the patient's blood and merging them with cancer cells, enabling the body to recognize and attack other similar cancer cells.〔 〕 In studies conducted in 2001 and 2003, 80% of test subjects showed improvement without harmful side effects.〔 (【引用サイトリンク】 publisher=Genoa Biotechnologia )〕 Though test groups were relatively small, the results of the studies show evidence that the drug is effective.〔 〕
==Procedure==
To create the vaccine, blood is drawn from the patient and monocytes specific to the patient are separated from the blood via apheresis. Dendritic cells are then derived by adding cytokines to the extracted monocytes. The dendritic cells are then fused with tumor cells through electrofusion, creating a "hybrid cell" of tumor and dendritic cells.〔 These hybrid cells are then injected back into the patient. The hybrid cells are recognized by the body's immune system and these cells and cells like it are marked for destruction. The tumor cells, which were previously unrecognized by the body's immune system are subsequently attacked. The entire procedure takes up to 30 days to complete.〔 〕
Each vaccine is specific to that patient. Though not a preventative measure, the vaccine's creator, Dr. Barbuto, predicted that the vaccine would be even more effective in patients in earlier stages of cancer. The vaccine is administered in conjunction with other cancer-preventative measures such as chemotherapy.〔
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「HybriCell」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|